SPEAKERS 2021 (2022 TO BE ANNOUNCED)
Below are the speakers that presented at the 4th annual E-Cigarette Summit 2021 – USA.
There is no doubt that the last 12 months have been one of the most challenging times in public health history and we are very grateful for all of the speakers both new and old who have agreed to commit their time to participate at this years Summit.
On behalf of our Chair, Professor Thomas J. Glynn and our esteemed speakers we warmly welcome you to the Summit 2021
Stanford Prevention Research Centre, Stanford University School of Medicine
Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS). Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch.. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse. Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments. He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award.
Professor Emeritus and Dean Emeritus
School of Public Health, University of Michigan
Kenneth E. Warner is the Avedis Donabedian Distinguished University Professor Emeritus of Public Health and Dean Emeritus at the University of Michigan School of Public Health, where he was on the faculty from 1972-2017. He served as Dean from 2005-2010 and as a department chair from 1982-88 and 1992-95. An economist, Dr. Warner earned his A.B. degree from Dartmouth College and M.Phil. and Ph.D. degrees from Yale University. Presented in over 250 professional publications, including 7 books, Dr. Warner’s research has focused on tobacco and health policy. Dr. Warner served as the World Bank’s representative to negotiations on the Framework Convention on Tobacco Control. He also served as the Senior Scientific Editor of the 25th anniversary Surgeon General’s report on smoking and health. During 2004-05 he was President of the Society for Research on Nicotine and Tobacco. He was a founding member of the Board of Directors of the Truth Initiative. Currently, he is a member of the FDA Tobacco Products Scientific Advisory Committee and a public member of the DHHS Interagency Committee on Smoking and Health. Dr. Warner’s honors and awards include: the Surgeon General’s Medallion, conferred by Dr. C. Everett Koop in 1989; election to membership in the National Academy of Medicine in 1996; a Luther L. Terry Award for Exemplary Leadership in Tobacco Control in 2003; the Alton Ochsner Award Relating Smoking and Disease in 2010; and the triennial Doll-Wynder Award from the Society for Research on Nicotine and Tobacco in 2017.
Professor of Medicine and Bioengineering & Theapeutic Sciences
University of California, San Franciso
Neal L. Benowitz, MD, is Emeritus Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969, following which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 700 research papers. Dr Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology. Dr Benowitz was a scientific editor of the 1988 United States Surgeon General’s Report on Smoking and Health: Nicotine Addiction; a scientific editor of the 2001 NCI Monograph 13 Report on Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine; and served as section editor for the 2010 Surgeon General’s Report on How Tobacco Smoke Causes Disease. He,has served as a member of the National Institutes of Health Pharmacology Study Section, the FDA Nonprescription Drug Advisory Committee and the FDA Tobacco Products Science Advisory Committee. He is a member of a number of medical societies, including the American Society for Clinical Investigation and the Association of American Physicians. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.
Senior Research Fellow and Editor, Cochrane Tobacco Addiction Group
Nuffield Department of Primary Care Health Sciences, University of Oxford
Jamie Hartmann-Boyce is a senior research fellow and departmental lecturer with the Centre for Evidence-Based Medicine at the Nuffield Department of Primary Care Health Sciences, University of Oxford. Her particular interests lie in evidence synthesis (both quantitative and qualitative) and the communication of complex information and data to inform policy and public action. Her research mainly consists of complex evidence synthesis work. She leads the Cochrane review of electronic cigarettes for smoking cessation, which is now a living review funded by Cancer Research UK, updated monthly, and is an editor for the Cochrane Tobacco Addiction Group.
Professor of Medicine, Harvard Medical School
Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston
Nancy Rigotti, MD, is an internationally known expert in tobacco use, tobacco cessation, and tobacco control public policy. Trained as a general internist, she is Associate Chief of the Division of General Internal Medicine at Massachusetts General Hospital, a Professor of Medicine at Harvard Medical School, and Past President of both the Society for Research in Nicotine and Tobacco and the Society of General Internal Medicine. Dr. Rigotti founded and directs the Tobacco Research and Treatment Center at Massachusetts General Hospital. It combines a clinical service (MGH Tobacco Treatment Smoking Service) with a multidisciplinary research group whose mission is to develop innovative and effective smoking cessation treatment and tobacco control policy approaches. Her research includes evaluations of tobacco control public policies and clinical trials of behavioral and pharmacologic smoking cessation treatments, with a focus on identifying system-level interventions suitable for various inpatient and outpatient health care settings in the U.S. and globally. She co-led the American College of Cardiology’s 2018 Consensus Decision Pathway on Tobacco Cessation Treatment. Dr. Rigotti was a member of the committee that produced the 2018 U.S. National Academies of Science, Engineering, and Medicine’s Report on the Public Health Consequences of Electronic Cigarettes. Her current work addressing the role of e-cigarettes for tobacco smoking cessation and harm reduction. Dr. Rigotti has authored over 300 publications.
Professor, Behavioural and Social Sciences & Internal Medicine
Brown University, School of Public Health & Alpert School of Medicine
Dr. Ahluwalia is a physician, public health scientist and professor at Brown University’s Schools of Public Health and Medicine, and is the Associate Director for Population Sciences at the Brown Cancer Center. He has been in academic medicine since 1992 and has been a practicing physician, faculty member, department chair, Associate Dean and Center Director in medical schools, and School of Public Health Dean. His primary research areas are health disparities and smoking cessation and nicotine addiction in African-American smokers. He has been continuously funded by NIH for 25 years and has published more than 350 manuscripts. Ahluwalia has served on the U.S. government’s National Advisory Council on Minority Health and Health Disparities, on the SRNT Board of Directors, and is currently appointed to the Interagency Committee on Smoking and Health chaired by the US Surgeon General. Dr. Ahluwalia trained at NYU, received a MD and MPH at Tulane University, a Medicine residency at UNC Chapel Hill, and a clinical epidemiology fellowship at Harvard Medical School, where he received a masters degree in health policy.
Professor of Tobacco Addiction
Institute of Psychiatry, Psychology & Neuroscience,, Kings College London
Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998. She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies. Competing Interest: None Stated
Director, Office of Health Communication & Education
FDA Center for Tobacco Products
Kathleen Crosby is currently Director of the Office of Health Communication and Education at the FDA Center for Tobacco Products (CTP). The office is responsible for conducting public education, stakeholder outreach, and regulatory communication programs designed to ensure FDA's success in implementing the Tobacco Control Act. These efforts include developing breakthrough communication strategies to reduce youth tobacco use, helping current tobacco users quit, and building stakeholder understanding of and compliance with FDA tobacco product regulations. Since joining CTP in February 2011, Ms. Crosby has led the development and implementation of multiple public education campaigns targeting at-risk and underserved populations, including FDA's first-ever national youth tobacco prevention campaign, "The Real Cost." From its launch in Feb. 2014 to Nov. 2016, the award-winning campaign has prevented up to 587,000 youth ages 11 to 19 from initiating smoking, half of whom might have gone on to become established adult smokers. Ms. Crosby's career spans 20 years of senior-level marketing and advertising experience working on large-scale multimedia campaigns and education programs for major national brands in both the private and non-profit sectors. Before beginning at CTP, Ms. Crosby was Senior Vice President, Group Campaign Director of the Washington office of the Ad Council, where she successfully managed day-to-day operations. In her nine years at the Ad Council, she created integrated communication programs that have proven to inspire attitudinal and behavioral change for America's most pressing social issues. One of Ms. Crosby's leadership roles at the Ad Council was as Campaign Director for 17 United States government agencies, including the Departments of Health and Human Services, Transportation, Homeland Security, Energy, Defense, Agriculture, and Justice. Previously, while serving as Vice President of Strategic Planning at Arnold Worldwide, Ms. Crosby oversaw the strategic development of the Legacy Foundation's "Truth" campaign, which is widely regarded as one of the most potent and successful tobacco prevention campaigns ever conducted in the United States. Ms. Crosby received a B.A. degree from University of Colorado in Political Science with a minor in Spanish.
Professor, College of Health Solutions
Arizona State University
Scott J. Leischow joined Arizona State University in June 2017, and is a Professor and the Director of Clinical and Translational Science. Prior to that, Leischow was at the Mayo Clinic Arizona from 2012-2017, where he led the Research on Health Equity and Community Health (REACH) Program and co-led cancer prevention and control within the Mayo Clinic Cancer Center. He was formerly an Associate Director at the University of Arizona Cancer Center and also served as Chief of the Tobacco Control Research Branch at the National Cancer Institute within National Institutes of Health and Senior Advisor for Tobacco Policy in the Office of the Secretary of the U.S. Department of Health and Human Services. Dr. Leischow completed his doctorate in Health Education from the University of Maryland, and a postdoctoral fellowship in Behavioral Pharmacology from Johns Hopkins University. Dr. Leischow has also received several awards, including the NIH Directors Award. Most of the work implemented by Dr. Leischow is translational in nature, and dedicated to moving research into practice and policy. His research and publications focus on pharmacologic and behavioral treatments for tobacco dependence, tobacco regulatory science, and systems and network approaches to population health. Dr. Leischow developed an early interest in telephone-based counseling as a volunteer and employee at the Racine Underground Safe House (RUSH). After joining the University of Arizona as a faculty member, his interest in providing telecounseling contributed to his decision to create and implement the Arizona Smokers Helpline, the third state quitline in the U.S. While in government, Dr. Leischow also played a leadership role on the development and implementation of the national smoking cessation quitline network, national smoking cessation website (smokefree.gov), national tollfree quitline number (1-800-QUITNOW), and an initiative to prohibit smoking on all Department of Health and Human Services campuses (TobaccFree HHS). Dr. Leischow is past president of the Society for Research on Nicotine and Tobacco (SRNT) and founding Editor-in-Chief of the journal Tobacco Regulatory Science.
Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy
School of Public Health, University of Michigan
Cliff Douglas is the Director of the University of Michigan Tobacco Research Network, an adjunct professor at the School of Public Health, and a co-principal investigator for the Center for the Assessment of Tobacco Regulations at the University of Michigan. He was the American Cancer Society’s Vice President for Tobacco Control from 2015 to 2020, where he led the development of a comprehensive new public health approach to tobacco control, set forth in the American Cancer Society Public Health Statement on Ending Combustible Tobacco Use in the United States (2018), and co-founded the National Partnership on Behavioral Health and Tobacco Use, which is dedicated to increasing cessation and reducing mortality and illness in smokers with mental health conditions. He also provided expertise on issues related to the changing tobacco product marketplace and guided ACS’s efforts to educate the public about the impact of smoking on COVID-19. Previously, he served as a policy advisor for the Assistant Secretary for Health and the U.S. Surgeon General in the Obama administration, where he was a lead author of the Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services. Earlier in his career, he coordinated the successful national campaign to make all commercial airline flights smoke-free and participated as an attorney and public health expert in the litigation that resulted in adoption of the Master Settlement Agreement. As special counsel for Congressman Martin Meehan and the Congressional Task Force on Tobacco and Health in the U.S. House of Representatives, he wrote legislation and prepared the 111-page prosecution memorandum that persuaded the U.S. Attorney General to launch a criminal investigation into the tobacco industry and later file the Justice Department’s landmark racketeering (RICO) action against the major tobacco companies. As told in Civil Warriors: The Legal Siege on the Tobacco Industry, Mr. Douglas also helped tobacco industry whistleblowers go public, and initiated an ABC News expose on the tobacco companies’ engineering of their products to cause dependency that led the Food and Drug Administration to open a two-year investigation and regulate tobacco for health and safety for the first time.
Professor of Population Health, Medicine and Psychiatry
NYU Grossman School of Medicine
My work over the last two decades has focused on innovative ways to reach and deliver tobacco use cessation treatment within health care, particularly to populations with low rates of treatment. Initially, consistent with recommendations at that time, I focused on referring all smokers to a multi-disciplinary smoking cessation program. However, I found that approach, despite a higher individual rate of success, had limited impact because of low acceptance of the referral by smokers and poor attendance at the program. As a result, I shifted my studies and policy efforts from a specialty-clinic model (referral to a smoking cessation clinic) to a primary care-based model. I have studied different approaches to increase tobacco use cessation treatment in primary care, such as use of an on-call counselor and simple referral to a telephone care coordination program for smoking. I have also studied use of a similar clinic-based approach in mental health care. More recently, I have been studying whether a population-based approach is even more successful at helping smokers to quit. We showed that by reaching out and recruiting from the entire population, proactive outreach in primary care led to a higher population-level quit rate in four medical centers, and we found the same approach worked equally well for smokers with mental health diagnoses. We now also testing whether an opt-out approach to smoking cessation is more effective in primary care and in mental health care. I am currently Principal Investigator on nine large grants, with funding from National Institutes of Health, VA Health Services Research and Development Service and others. For the last 5 years, I have been increasingly studying patterns of use of alternative tobacco products, including electronic cigarettes, hookah and midwakh (a tobacco pipe used frequently in parts of the Middle East). We are currently conducting studies looking at the process and impact of switching from combustible cigarettes to electronic cigarettes.
Principal Investigator, Monitoring the Future
Institute for Social Research, University of Michigan
Richard Miech is a Research Professor at the University of Michigan's Institute for Social Research and Principal Investigator of Monitoring the Future. He received his Ph.D. degree in Sociology from the University of North Carolina at Chapel Hill and a MPH degree from Johns Hopkins University. His work focuses on trends in substance use, with an emphasis on disentangling how these trends vary by age, historical period, and birth cohort membership. Other research interests include the rapid growth of vaping in recent years and its long-term consequences, as well as the effects of recreational marijuana laws on adolescent substance use.
Dep't of Health Care Organization & Policy, School of Public Health,University of Alabama at Birmingham
Ruoyan Sun is an Assistant Professor in the Department of Health Care Organization and Policy at UAB School of Public Health. Trained in health economics and operations research, she applies a variety of quantitative methods to evaluate tobacco control policies. Her research focus on three main topics. First one is policy simulation, specifically modeling and simulating changes in smoking behaviors (initiation and cessation) via agent based modeling. The second one utilizes optimal control methods with mathematical models to assess optimal mix of interventions to reach tobacco control goals. Using survey data, she also examines risk factors for adolescent vaping in the US. Recently, Dr. Sun started a new line of research, mining social media data on e-cigarettes for content and sentiment analysis. Dr. Sun received her undergraduate degree from College of William and Mary, a master’s degree from Johns Hopkins University and her Ph.D. from the University of Michigan.
Dept of Health Policy & Management, Yale School of Public Health
Abigail S. Friedman is an Assistant Professor in the Department of Health Policy and Management at the Yale School of Public Health. Her research focuses on the policy determinants of tobacco use and disparities therein, with the overarching goal of informing and facilitating evidence-based policymaking to improve population health and reduce inequality. A health economist by training, she conducts work in three areas. The first uses quasi-experimental methods to estimate the effects of federal, state, and local policies on conventional and electronic cigarette use, in order to inform more nuanced policymaking that accounts for the differing health impacts of these products. The second line of research considers how new tobacco products are affecting disparities in tobacco use, particularly by socioeconomic status and mental health. Finally, her work on mental health disparities in tobacco use focuses on identifying the drivers behind these differentials as well as potential means to close these gaps, particularly among adolescents and young adults. Dr. Friedman received her undergraduate degree from Columbia University and her Ph.D. in the economics concentration of Harvard University’s Ph.D. Program in Health Policy.
Assistant Professor in Health Administration and Policy, School of Community Health Sciences
University of Nevada, Reno School of Community Health Sciences
Jennifer Pearson is an Assistant Professor in Health Administration and Policy in the School of Community Health Sciences at the University of Nevada, Reno. Broadly, her research focuses on how regulation of tobacco and cannabis product characteristics, packaging, and advertising affects consumer behavior and public health outcomes. Dr. Pearson has authored over 100 scientific peer-reviewed scientific articles on tobacco and cannabis policy and published in high-impact journals such as the New England Journal of Medicine, the American Journal of Public Health, and Tobacco Control, and is a Deputy Editor of Nicotine & Tobacco Research. Dr. Pearson earned her doctorate in Public Health from the Johns Hopkins Bloomberg School of Public Health in 2011, and her Master of Public Health degree from George Washington University in 2007. Dr. Pearson started her career in public health as a Tobacco Education Coordinator for the American Lung Association of Nevada and served as a US Peace Corps volunteer in Guinea from 2002-2004.
South Carolina Division of Tobacco Prevention and Control
Jaron King, MS, is the surveillance coordinator for the South Carolina Division of Tobacco Prevention and Control. He is also a first year PhD student at the University of South Carolina’s Arnold School of Public Health. His research experience has been in health communication and is chiefly responsible for tobacco surveillance activities in his current role with the South Carolina state health department. As a relatively new researcher to the field of tobacco control, Mr. King is concerned with addressing health disparities in tobacco use within his state particularly among youth.
The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.
Director, Office of Science (OS),Center for Tobacco Products (CTP)
U.S. Food and Drug Administration
Matthew R. Holman, Ph.D. is currently Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration (FDA). He was appointed to that position in January 2017. The Office of Science at CTP is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal, they provide the scientific support for regulations and guidance, review tobacco product applications, evaluate the knowledge basis for regulatory decisions, and carry out research to fill the gaps in scientific knowledge related to tobacco product regulation. He received his Ph.D. in Biochemistry from the University of Maryland at College Park in 2000. Before taking on his current position, Dr. Holman served as Director of the Division of Product Science within CTP’s Office of Science for six years. In this position, he oversaw evaluation of the composition and design of tobacco products. In addition, he was involved in chemical, microbiological, and engineering research on tobacco products, resulting in numerous publications in peer-reviewed scientific journals. During this time, Dr. Holman also served as Technical Project Lead (TPL) in reviewing over a thousand SE Reports. As TPL, he was responsible for the overall scientific review of SE Reports by CTP. Before his tenure at CTP, he worked in FDA’s Center for Drug Evaluation and Research (CDER) on over-the-counter drug products. He served in a few positions within CDER, with his last position being Deputy Director of the Division of Nonprescription Regulation Development. In this role, he was involved in the publication of approximately 50 rulemakings, guidance documents, and other Federal Register notices.
Chief Impact Officer
David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson. In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role. David is a graduate of Columbia University with a Master’s in Public Policy & Administration.
Counterfactual Consulting Ltd
Clive Bates has had a diverse career in the public, private and not-for-profit sectors. He started out with the IT company, IBM, then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.
- Stefanie Miller is an investment analyst with FiscalNote Markets in Washington, D.C., where she leads the tobacco, cannabis, politics and fiscal policy practice areas. She specializes in the legal and political risks to the tobacco sector stemming from FDA tobacco regulations, Congressional tobacco control efforts, innovative products entering the nicotine market, and incumbent public health distrust of “Big Tobacco.” Stefanie has worked at the intersection of Wall Street and Washington since 2007, prior to which she worked in federal politics. Stefanie received her MBA from Georgetown University and her BA in economics and political science from the University of Nebraska. She appears frequently as a commentator on CNBC, Yahoo Finance, and Bloomberg TV and is quoted regularly in financial press.
Professor of Oncology
Lombardl Comprehensive Cancer Center, Georgetown University
David Levy has a PhD in Economics from UCLA and is currently a Professor of Oncology at Georgetown. He has published over 200 papers, including articles in the American Economic Review, American Journal of Public Health, JAMA, Lancet, Medical Care, American Journal of Preventive Medicine, Obesity Review, Tobacco Control, and the Review of Economics and Statistics. His work spans topics in public health and industry behavior. Dr. Levy has been principal investigator of grants from the Centers for Disease Control and Prevention, the World Health Organization, the National Cancer Institute, the National Institute on Drug Abuse, Bloomberg/Gates Foundation, European Union, and the Robert Wood Johnson Foundation. He is currently the principal investigator of an FDA TCORS, and grants from the National Cancer Institute to the ITC project and to the CISNET Lung group. Dr. Levy oversees the design and development of the SimSmoke tobacco policy simulation model, which predicts the effect of tobacco policies, such as tax increases, smoke-free air laws, media campaigns, youth access policies, and cessation treatment policies, on smoking rates and tobacco-related deaths. He has developed models for 10 states and for over 60 countries. He is currently developing simulation models that incorporate the use of smokeless tobacco and e-cigarettes.
Dean and Professor of Public Health Policy and Management
School of Global Public Health, New York University
Dr. Healton is the dean of the School of Global Public Health at New York University, Director of the Global Institute of Public Health and Professor of Public Health Policy and Management. Prior to this appointment, Dr. Healton served as President and Chief Executive Officer of Legacy, the leading national foundation dedicated to tobacco control. During her 14-year tenure with the foundation, she guided the highly acclaimed, national youth tobacco prevention counter-marketing campaign, truth®, which has been credited in part with reducing youth smoking prevalence to record lows. Prior to Legacy, Dr. Healton held numerous roles at Columbia University including Assistant Vice President and Associate Dean for the Health Sciences; Chairman of Sociomedical Sciences; and Associate Dean of the Mailman School of Public Health. She has authored over 120 peer-reviewed articles and special reports, and has been awarded multiple grants in AIDS, tobacco control and higher education. Dr. Healton also serves on numerous non-profit boards including HealthRight International and Action on Smoking and Health. Dr. Healton holds a DrPH from Columbia University's School of Public Health (with distinction) and an MPA in Public Administration from NYU Wagner in Health Policy and Planning.
Youdan Consulting - New Zealand
Ben Youdan has campaigned professionally for nearly 20 years, and has over a decade of experience leading charitable organisations in the UK and New Zealand. His career has taken us from running the biggest health awareness day in the UK, to setting up a major community initiative in south Auckland. He's run government funded social marketing programmes the UK and New Zealand, headed political campaign teams and been a regular media commentator. He moved to New Zealand in 2006 to run ASH, where he campaigned for the Smokefree 2025 goal. He left ASH in 2013 to lead the election campaign for the Green Party where he overhauled the campaign systems, delivering the biggest ever ground campaign in the Party’s history.
Australian Drug Law Reform
Dr Alex Wodak is a physician who was Director of the Alcohol and Drug Service, St. Vincent’s Hospital, Sydney (1982-2012) but has now retired. Major interests include prevention of HIV among people who inject drugs, prevention of alcohol problems and drug policy reform. Dr. Wodak is President of the Australian Drug Law Reform Foundation and was President of the International Harm Reduction Association (1996-2004). He helped establish the first needle syringe programme and the first supervised injecting centre in Australia when both were pre-legal and often works in developing countries on HIV control among among people who inject drugs. Dr Wodak helped establish the National Drug and Alcohol Research Centre, the Australian Society of HIV Medicine and the NSW Users AIDS Association.
Action on Smoking and Health (UK)
Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the National Institute for Health and Care Excellence committee which developed guidance for England on tobacco harm reduction and of an expert advisory group to the UK’s medicines regulator the MHRA on e-cigarettes. She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes. Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group. She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health. Competing Interest: None Stated
Professor of Psychology and IHRP Director
University of Illinois, Chicago
Robin Mermelstein, PhD. is Distinguished Professor, Psychology Department; Director of the Institute for Health Research and Policy at the University of Illinois at Chicago (UIC), and Co-Director of UIC’s Center for Clinical and Translational Science. Dr. Mermelstein has been active in health-behavior research for 30 years, with continuous NIH funding as a Principal Investigator on grants since 1986. Dr. Mermelstein was acknowledged by the NCI as a Research Pioneer in the Division of Cancer Control and Population Sciences. She is nationally recognized for her expertise in understanding trajectories and developmental patterns of youth tobacco use, for employing novel approaches to studying contextual factors in the development of nicotine dependence and health risk behaviors, for developing innovative health behavior clinical interventions for adolescents and adults, and for methodological issues in conducting tobacco-related research. She has been the PI of several large-scale, multidisciplinary program project and center grants, as well as the Director of a national program or the Robert Wood Johnson Foundation. Dr. Mermelstein has served on many NIH advisory and review committees, including being a former standing member of the NCI-A Cancer Centers review committee; a former member of the External Scientific Advisory Panel for the NCI’s Science of Research and Technology Branch; co-Chair of the NCI’s Tobacco Control Priorities Consultant Group; a former standing member of the National Institute on Drug Abuse’s K-award study section; and a current member of the External Scientific Advisory Board for the Adolescent Brain and Cognitive Development Study (ABCD Study) of NIH. She has been acknowledged for her scientific accomplishments by several national and international research societies, including being named a Fellow of the Association of Psychological Science, a Fellow of the Society of Behavioral Medicine, and a Fellow of the Society for Research in Nicotine and Tobacco. She is a past President of the Society for Research on Nicotine and Tobacco (2015-2016).
Professor, Dep't Psychiatry & Behavioural Sciences
Medical University of South Carolina
Prof Cummings is a Professor in the Department of Psychiatry & Behavioral Sciences at the Medical University of South Carolina where he co-leads the tobacco control research program. Over his nearly 40 year public health career he has published over 530 scientific papers on a wide range of topics including studies evaluating methods for smoking cessation, consumer risk perceptions, evaluations of mass media campaigns, tobacco product marketing, the impact of cigarette design on smoking behaviors, tobacco industry documents, and the impact of public policies on tobacco use behaviors.
Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab
School of Global Public Health, New York University
Dr. Niaura is a Professor of Social and Behavioral Health at NYU GPH and the Co-Director of the Tobacco Research Lab. His research interests are two-fold: studying the bio-behavioral substrates of tobacco dependence, including factors that influence adolescent and early adult tobacco use trajectories; and evaluating behavioral and pharmacological treatments for cessation, specifically with regard to addressing public health disparities in tobacco related burdens of illness and disability. He comes to NYU from the Washington, DC-based Schroeder Institute (SI) for Tobacco Research and Policy Studies where he was Director of Science and Training for eight years. Dr. Niaura has extensive expertise in tobacco dependence and treatment, having published over 400 peer-reviewed articles, commentaries and book chapters in this field. He has been PI or co-I of over 70 NIH-funded grants and is the former President of the Society of Nicotine and Tobacco Research.
Associate Professor, Dep't of Economics
Andrew Young School of Policy Studies, Georgia State University
Michael Pesko is a health economist and an Associate Professor in the Department of Economics at Georgia State University. Dr. Pesko’s research uses retrospectively-collected data and quasi-experimental methods to evaluate health policy changes. Dr. Pesko is particularly interested in policy changes affecting the use of e-cigarettes (see: e-cigarette research summary). Dr. Pesko has published over 40 peer reviewed papers in journals such as Journal of Human Resources, Journal of Risk and Uncertainty, Journal of Health Economics, American Journal of Health Economics, Health Economics, Health Affairs, Health Services Research, and American Journal of Public Health. His research has been supported by externally generated funds exceeding $2.8 million since 2016, including from the National Institute on Drug Abuse, National Cancer Institute, and the American Cancer Society. Dr. Pesko was hired by GSU in 2017 as part of the second-century initiative (2CI). Prior to joining GSU, Dr. Pesko was previously an Assistant Professor at Weill Cornell Medical College and a fellow at the Centers for Disease Control and Prevention. He graduated with a PhD in Economics in 2012.
Drug Policy Alliance
Described by Rolling Stone as "the point man" for drug policy reform efforts and “the real drug czar,” Ethan Nadelmann is widely regarded as the outstanding proponent of drug policy reform both in the United States and abroad. He founded and directed (from 2000 to 2017) the Drug Policy Alliance. Ethan was born in New York City and received his BA, JD, and PhD from Harvard, and a master’s degree in international relations from the London School of Economics. He then taught politics and public affairs at Princeton University from 1987 to 1994, where his speaking and writings on drug policy attracted international attention. He has authored two books on the internationalization of criminal law enforcement – Cops Across Borders and (with Peter Andreas) Policing The Globe – and his writings have appeared in most major media outlets in the U.S. as well as top academic journals (e.g., Science, International Organization), policy journals (Foreign Affairs, Foreign Policy, Washington Quarterly, Public Interest) and political publications from the right (National Review) to the left (The Nation). He is interviewed frequently by media, including The Colbert Report, The O’Reilly Factor, Real Time with Bill Maher, and news programs on all the major U.S. networks as well as dozens of networks elsewhere. His TED Talk, delivered at TEDGlobal in Rio de Janeiro in October 2014, has more than 2 million views, with translations into 28 languages. In 1994, Ethan founded the Lindesmith Center, a drug policy institute created with the philanthropic support of George Soros. A year later, he co-founded the Open Society Institute’s International Harm Reduction Development (IHRD) program. In 2000, the growing Center merged with the Drug Policy Foundation to form the Drug Policy Alliance. Ethan currently serves on the advisory board of the Open Society Foundation’s Global Drug Policy Project (GDPP) and as an advisor to the Global Commission on Drug Policy. He has played a key role as drug policy advisor to George Soros and other prominent philanthropists as well as elected officials ranging from mayors, governors and state and federal legislators in the U.S. to presidents and cabinet ministers outside the U.S. He is hosto of the forthcoming podcast "Psychoactive".
If you cannot see the full list of speakers required for this page please make sure you have ordered all speakers in your custom list.
Edit Custom Order Here »
Only administrators can see this message